instruction:
In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
question:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Restore Fiscal Discipline and 
Safeguard Social Security Act of 2002''.

SEC. 2. FINDINGS AND PURPOSES.

    (a) Findings.--The Congress finds the following:
            (1) When Congress enacted the fiscal year 2002 budget 
        resolution, it did so based on the assurance that the 
        Government would balance the budget without relying on social 
        security surpluses for the remainder of the decade and beyond. 
        Congress was also assured that it would not have to act to 
        increase the statutory debt limit until 2008.
            (2) The Government is projected to run on-budget deficits 
        that will require it to spend the social security and medicare 
        trust fund surpluses for the rest of the decade, even before 
        additional spending for defense and homeland security is 
        counted, and after the economy recovers and returns to strong 
        growth.
            (3) The total debt is increasing because we have not kept 
        the commitment to save the social security and medicare trust 
        fund surpluses. The Secretary of the Treasury has formally 
        requested that Congress increase the statutory limit on the 
        public debt by $750 billion, from the current level of $5.95 
        trillion to $6.70 trillion. Congress will have to vote to raise 
        the debt limit because we have been borrowing those trust fund 
        surpluses to cover a deficit in the rest of the budget instead 
        of saving them.
            (4) A $750 billion increase in the debt limit would be the 
        second largest increase in history and is irresponsible in the 
        absence of a framework to protect taxpayers from even further 
        increases in the national debt.
            (5) Congress should authorize a limited increase in the 
        debt limit to prevent a financial default, but should also work 
        together with the President to develop a plan to restore fiscal 
        discipline before further increasing our debt.
            (6) Current law provides for enforcement of budget 
        resolutions:
                    (A) Legislation violating discretionary spending 
                totals set in a budget resolution or the suballocations 
                set by the Committee on Appropriations is subject to a 
                point of order under section 302(f) of the 
                Congressional Budget Act of 1974.
                    (B) Legislation reducing receipts below a budget 
                resolution's total is subject to a point of order under 
                section 311(a) of the Congressional Budget Act of 1974.
    (b) Purpose.--The purpose of this Act is--
            (1) to provide a responsible, measured increase in the debt 
        limit to ensure that the Government meets its current legal 
        obligations;
            (2) effective immediately thereafter, to limit strictly the 
        size of further increases in the debt limit until the enactment 
        of a plan to bring the budget into balance in five years 
        without reliance on the social security trust fund surplus, 
        such that any larger increase in the debt limit this fall would 
        require a plan to balance the budget in fiscal year 2007, but 
        if this deficit reduction should prove insufficient, the 
        restrictions are automatically reestablished by the next 
        regular semi-annual report of the Congressional Budget Office;
            (3) to require that the President submit a budget plan 
        before the end of this fiscal year to achieve balance, without 
        reliance on the social security trust fund surplus, by fiscal 
        year 2007;
            (4) as a backup and discipline for these debt limit 
        provisions, to establish points of order against any budget 
        resolution that does not within five years and in all 
        subsequent years eliminate any deficits projected by the 
        Congressional Budget Office, without reliance on the social 
        security trust fund surplus, using the enforcement provisions 
        in current law to require that all subsequent spending and tax 
legislation conform to the budget resolution's deficit-reduction plan; 
and
            (5) thereby to restore fiscal discipline and to preserve 
        social security for future retirees.

                    TITLE I--INCREASE IN DEBT LIMIT

SEC. 101. INCREASE IN DEBT LIMIT.

    (a) Increase in Statutory Debt Limit.--Section 3101(b) of title 31, 
United States Code, is amended by striking ``$5,950,000,000,000'' and 
inserting ``$6,100,000,000,000''.
    (b) Point of Order.--(1) Effective immediately, except as provided 
by paragraph (2) or (3), it shall not be in order in the House of 
Representatives or the Senate to consider any bill, joint resolution, 
amendment, or conference report that includes any provision that 
increases the limit on the public debt above the limit set forth in 
section 3101(b) of title 31, United States Code, as in effect 
immediately before the date of consideration of that measure by more 
than $100,000,000,000.
    (2) Except as provided by paragraph (3), any bill or joint 
resolution may carry an increase in such limit of more than 
$100,000,000,000 only if the concurrent resolution on the budget for 
the budget year has been adopted and--
            (A) sets forth or assumes a budget that is in on-budget 
        balance or surplus within 4 fiscal years after the budget year 
        and is in on-budget balance or surplus for every subsequent 
        fiscal year covered by that resolution; and
            (B) does not contain any reduction in social security 
        benefits.
    (3) Paragraphs (1) and (2) shall not apply in the House of 
Representatives or the Senate if the chairman of the Committee on the 
Budget of the House or of the Senate, as applicable, certifies, based 
on the report of the Congressional Budget Office pursuant to section 
202(e)(1) or (2) of the Congressional Budget Act of 1974, whichever 
report is the most recent, that the budget will be in on-budget balance 
or surplus within 4 fiscal years after the budget year and is in on-
budget balance or surplus for every subsequent fiscal year covered by 
that report. If legislation to extend the discretionary spending limits 
beyond fiscal year 2002 is enacted before the date of release of such 
report, the Congressional Budget Office shall assume such discretionary 
spending levels. Any such certification shall only have force and 
effect until the date of submission of the next report under either 
such section.

SEC. 102. PRESIDENTIAL PLAN TO BALANCE THE BUDGET.

    (a) Presidential Plan.--The President shall submit to the Congress 
by September 30, 2002, a proposal to bring the budget of the Government 
(excluding the receipts and disbursements of the Federal Old-Age and 
Survivors Insurance Trust Fund and the Federal Disability Insurance 
Trust Fund) into balance or surplus by fiscal year 2007.
    (b) Sense of Congress.--It is the sense of Congress that the plan 
described in subsection (a) should be based on the most recent economic 
and technical assumptions of the Congressional Budget Office.

          TITLE II--CIRCUIT BREAKER TO PROTECT SOCIAL SECURITY

SEC. 201. CIRCUIT BREAKER TO PROTECT SOCIAL SECURITY.

    (a) Circuit Breaker Points of Order.--(1) Effective January 1, 
2003, whenever the most recent report of the Congressional Budget 
Office pursuant to section 202(e)(1) of the Congressional Budget Act of 
1974 projects an on-budget deficit for any fiscal year, it shall not be 
in order in the House of Representatives or the Senate to consider any 
concurrent resolution on the budget that--
            (A) sets forth or assumes an on-budget deficit for any such 
        fiscal year that is larger than such Congressional Budget 
        Office projection for that fiscal year;
            (B) sets forth or assumes a budget that is not in on-budget 
        balance or surplus within 4 fiscal years after the budget year 
        and is not in on-budget balance or surplus for any subsequent 
        fiscal year covered by that resolution; or
            (C) contains any reduction in social security benefits.
    (2) Effective January 1, 2003, whenever the most recent report of 
the Congressional Budget Office pursuant to section 202(e)(1) of the 
Congressional Budget Act of 1974 projects both on-budget surpluses (or 
a balanced budget) and deficits for the fiscal years included in that 
report, it shall not be in order in the House of Representatives or the 
Senate to consider any concurrent resolution on the budget that--
            (A) sets forth or assumes an on-budget deficit for any 
        fiscal year for which such Congressional Budget Office 
        projection for that fiscal year is for an on-budget surplus or 
        balance; or
            (B) contains any reduction in social security benefits.
    (b) Suspension of Requirement During War or Low Economic Growth.--
            (1) Low growth.--If the most recent of the Department of 
        Commerce's advance, preliminary, or final reports of actual 
        real economic growth indicate that the rate of real economic 
        growth (as measured by real GDP) for each of the most recently 
        reported quarter and the immediately preceding quarter is less 
        than 1 percent, this section is suspended.
            (2) War.--If a declaration of war is in effect, this 
        section is suspended.
answer:
Restore Fiscal Discipline and Safeguard Social Security Act of 2002 - Amends Federal money and finance law to increase the statutory debt limit to $6.1 trillion.Makes it out of order for the House of Representatives or the Senate to consider any bill or amendment that increases the public debt limit above the new one established by this Act by more than $100 billion, except in specified circumstances.Directs the President to submit to Congress a proposal to bring the budget of the Government (excluding the Federal Old-Age and Survivors Insurance Trust Fund and the Federal Disability Insurance Trust Fund) into balance or surplus by FY 2007.Makes it out of order for the House or the Senate, whenever the most recent CBO report projects an on-budget deficit for any fiscal year, to consider any concurrent resolution on the budget that: (1) sets forth or assumes an on-budget deficit for any such fiscal year larger than such projection; (2) sets forth or assumes a budget that is not in on-budget balance or surplus within four fiscal years, and is not in on-budget balance or surplus for any covered subsequent fiscal year; or (3) contains any reduction in social security benefits.Makes it out of order for the House or the Senate, whenever the most recent CBO report projects both on-budget surpluses (or a balanced budget) and deficits for the fiscal years concerned, to consider any concurrent resolution on the budget that: (1) sets forth or assumes an on-budget deficit for any fiscal year for which the CBO projection is for an on-budget surplus or balance; or (2) contains any reduction in social security benefits.Suspends such requirements during war or low economic growth.


question:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``National Institute on Minority 
Health Act''.

SEC. 2. FINDINGS.

The Congress finds that--
            (1) heart disease and strokes lead to about 2\1/2\ times as 
        many deaths among Black Americans (between the ages of 25 and 
        44) as among White Americans;
            (2) diabetes is twice as prevalent among Mexican- and 
        Puerto Rican-Americans as among White Americans;
            (3) Black and Hispanic women account for 73 percent of the 
        reported cases of AIDS among American women, and the death rate 
        from AIDS is 9 times higher among Black women than among White 
        women;
            (4) between 1983 and 1985, when the infant mortality rate 
        among Whites was 9.0 deaths per 1,000 live births, the infant 
        mortality rate among Blacks was 18.7 and 13.9 among Native 
        Americans, with similar disparities among rates of low-
        birthweight babies;
            (5) in 1988, when the rates of death resulting from 
        homicides was 8 per 100,000 among young (ages 15 to 24) White 
        males, the rate among young Black males was 59 per 100,000, and 
        the rates for young Hispanic and Native American males was 
        roughly 2 to 3 times that of young White males;
            (6) biomedical research, including clinical trials for 
        pharmaceuticals, often has failed to include minorities in the 
        population being studied or tested, even when it is certain 
        that minorities will be among the population subject to the 
        medical condition or receiving the treatment or pharmaceutical 
        that is being studied or tested;
            (7) the percentages of medical professionals, especially 
        physicians, who are minorities are significantly lower than 
        their representation in the general population; and
            (8) the ratio of physicians to inhabitants of neighborhoods 
        that are heavily populated by minorities (or low-income 
        residents) is often much lower than the ratio of physicians to 
        inhabitants of predominantly White neighborhoods.

SEC. 3. ESTABLISHMENT OF NATIONAL INSTITUTE ON MINORITY HEALTH.

    Part C of title IV of the Public Health Service Act (42 U.S.C. 285 
et seq.), as amended by section 124 of Public Law 102-321 (106 Stat. 
364), is amended by adding at the end the following subpart:

          ``Subpart 17--National Institute on Minority Health

                         ``purpose of institute

    ``Sec. 464V. (a) The general purpose of the National Institute on 
Minority Health is the conduct and support of research, training, the 
dissemination of health information, and other programs with respect to 
minority health conditions, including the advancement of opportunities 
for and recruitment of minorities for training and placement as health 
professionals.
    ``(b) For purposes of this subpart:
            ``(1) The term `health care system' means the system in the 
        United States for the delivery of health care.
            ``(2) The term `minorities' means members of minority 
        groups.
            ``(3) The term `minority health conditions' means all 
        diseases, disorders, and conditions (including conditions 
        regarding mental health)--
                    ``(A) unique to, more serious in, or more prevalent 
                in minorities;
                    ``(B) for which the factors of medical risk or 
                types of medical intervention are different for 
                minorities, or for which it is unknown whether such 
                factors or types are different for minorities; or
                    ``(C) with respect to which there has been 
                insufficient clinical research involving minorities as 
                subjects, or insufficient clinical data on minorities.
            ``(4) The term `research on minority health' means research 
        on minority health conditions.
            ``(5) The term `Institute' means the National Institute on 
        Minority Health.

                         ``certain authorities

    ``Sec. 464W. (a) In carrying out section 464V, the Director of the 
Institute shall--
            ``(1) recommend an agenda for conducting and supporting 
        research on minority health;
            ``(2) identify projects of research on minority health that 
        should be conducted or supported by the national research 
        institutes;
            ``(3) identify multidisciplinary research relating to 
        research on minority health that should be so conducted or 
        supported;
            ``(4) promote coordination and collaboration among entities 
        conducting research identified under paragraph (2) or (3);
            ``(5) encourage the conduct of research identified under 
        paragraph (2) or (3) by entities receiving funds from the 
        national research institutes;
            ``(6) ensure that minorities are appropriately represented 
        as subjects in projects of clinical research conducted or 
        supported by the national research institutes and, as 
        appropriate, encourage similar representation in research 
        conducted under other circumstances; and
            ``(7) promote the sufficient allocation of the resources of 
        the national research institutes for conducting and supporting 
        such research.
    ``(b)(1) The Director of the Institute shall monitor the health 
care system for the purpose of determining the effects of the system on 
the health of minorities, including the extent to which minorities have 
access to health care. In monitoring the system, the Director shall 
determine, with respect to such purpose, the effects of the policies 
and practices of entities that provide health benefits plans.
    ``(2) With respect to Federal proposals for reforming the health 
care system, the Director of the Institute shall, in carrying out 
paragraph (1), monitor such proposals for the purpose of determining 
whether the proposals adequately provide for the health of minorities.
    ``(c)(1) The Director of the Institute shall serve as an advocate 
regarding the health of minorities. The Director may in so serving 
carry out advocacy activities regarding the Federal Government, State 
and local governments, and private entities, including public and 
private educational entities.
    ``(2) In carrying out paragraph (1), the Director of the Institute 
shall determine the health benefits for minorities that should, at a 
minimum, be provided for in any reform of the health care system.
    ``(d) The Director of the Institute shall encourage the creation of 
opportunities for the training of minorities as health professionals 
and shall facilitate the placement of minorities trained as health 
professionals into appropriate positions.''.

SEC. 4. CONFORMING AMENDMENT.

    Section 401(b)(1) of the Public Health Service Act (42 U.S.C. 
281(b)(1)), as amended by section 121 of Public Law 102-321 (106 Stat. 
358), is amended by adding at the end the following subparagraph:
            ``(Q) The National Institute on Minority Health.''.
answer:
National Institute on Minority Health Act - Amends the Public Health Service Act to declare that the National Institute on Minority Health's purpose is the conduct and support of research, training, information dissemination, and other programs regarding minority health, including the advancement of opportunities for and recruitment of minorities for training and placement as health professionals.  Adds the Institute to the list of research institutes of the National Institutes of Health.


question:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Medicare Market Acquisition Drug 
Price Act of 2002''.

SEC. 2. REFORM OF PAYMENT FOR DRUGS AND BIOLOGICALS UNDER THE MEDICARE 
              PROGRAM.

    (a) Payment Reform.--
            (1) In general.--Section 1842(o) of the Social Security Act 
        (42 U.S.C. 1395u(o)) is amended to read as follows:
    ``(o) Payment for Drugs and Biologicals.--
            ``(1) General rule.--If a physician's, supplier's, or any 
        other person's bill or request for payment for services 
        includes a charge for a drug or biological for which payment 
        may be made under this part and the drug or biological is not 
        paid on a cost or prospective payment basis as otherwise 
        provided in this part, the amount payable for the drug or 
        biological shall be based on the following:
                    ``(A) Multi-source (generic) drugs.--In the case of 
                a drug or biological that meets the requirements for a 
                multi-source drug under subclauses (I) and (II) of 
                section 1927(k)(7)(A)(i), 105 percent of the volume-
                weighted median average acquisition price for any drug 
                or biological covered under the same medicare HCPCS 
                code.
                    ``(B) Single source (brand) drugs and 
                biologicals.--In the case of a drug or biological that 
                meets the requirements for a single source drug under 
                section 1927(k)(7)(A)(iv), 105 percent of the average 
                acquisition price for the drug or biological.
                    ``(C) Access exception.--The Secretary may modify 
                the rate otherwise applicable in order to assure access 
                to necessary drugs and biologicals in the case of sole 
                community providers in rural and other areas where the 
                providers are not reasonably able to obtain the drugs 
                and biologicals at the payment rates otherwise 
                applicable. Such modification shall not result in a 
                change of more than 15 percent of the rate otherwise 
                applicable.
                    ``(D) Data-related exception.--If the Secretary 
                determines that there is insufficient data available 
                with respect to compute an average acquisition price 
                for a drug or biological for a quarter or that, because 
                of a significant change in price from quarter-to-
                quarter, the available data on the average acquisition 
                price does not accurately reflect the actual, current 
                acquisition cost for the drug or biological, the 
                Secretary may substitute for the quarters involved an 
                appropriate payment for the drug or biological for such 
                average acquisition price.
                    ``(E) Application of ndc codes.--If the Secretary 
                determines that it is appropriate to provide for 
                payment under this subsection using national drug code 
                (NDC) instead of HCPCS codes, in applying subparagraph 
                (A) the reference to the same HCPCS code shall be 
                deemed a reference to the appropriate national drug 
                codes for those drugs or biologicals that are 
                therapeutically and pharmaceutically equivalent and 
                bioequivalent (as defined for purposes of section 
                1927(k)(7)(A)).
            ``(2) Definition of average acquisition price.--
                    ``(A) In general.--For purposes of this subsection, 
                the term `average acquisition price' means, with 
                respect to a drug or biological and with respect to 
                each dosage form and strength of the drug or biological 
                product (without regard to any special packaging, 
                labeling, or identifiers on the dosage form or product 
                or package), the average of all final sales prices 
                charged by the manufacturer of the drug or biological 
                product in the United States, excluding sales exempt 
from inclusion in the calculation of best price under section 
1927(c)(1)(C) (other than under clause (ii)(III) of such section) and 
excluding sales subject to a rebate under section 1927, as reported 
under paragraph (3).
                    ``(B) Net price.--Such average acquisition price 
                shall be calculated net of all of the following (as 
                estimated by the Secretary):
                            ``(i) Volume discounts.
                            ``(ii) Prompt pay discounts and cash 
                        discounts.
                            ``(iii) Charge-backs.
                            ``(iv) Short-dated product discounts (for 
                        spoilage and other factors).
                            ``(v) Free goods and services.
                            ``(vi) Rebates.
                            ``(vii) All other price concessions 
                        provided by the drug manufacturer.
                The Secretary may make subsequent adjustments in such 
                average acquisition price to take into account updated 
                information and differences between the price 
                previously estimated and the actual average acquisition 
                price.
                    ``(C) Weighting.--The average of all final sales 
                prices described in subparagraph (A) shall be 
                determined by dividing--
                            ``(i) the sum of all final prices charged 
                        by the manufacturer (net of the adjustments 
                        made under subparagraph (B)) for sales in the 
                        period involved that are included in 
                        subparagraph (A) for the drug or biological, by
                            ``(ii) the total number of units of such 
                        sales in the period.
                    ``(D) Distribution of reports.--The Secretary shall 
                promptly distribute applicable payment rates under this 
                subsection to carriers and fiscal intermediaries and 
                other contractors that make payment for drugs and 
                biologicals under this section in order to apply a 
                uniform reimbursement rate under this section.
            ``(3) Price reporting requirement.--
                    ``(A) In general.--As a condition for payment for 
                any drug or biological of a manufacturer under this 
                subsection, the manufacturer of the drug or biological 
                shall--
                            ``(i) report, on a quarterly basis, to the 
                        Secretary (or the Secretary's designee) the 
                        manufacturer's average acquisition price and 
                        the information required under subparagraph (C) 
                        for all drugs and biologicals of the 
                        manufacturer by national drug code (NDC);
                            ``(ii) maintain such records (in written or 
                        electronic form) regarding such sales and 
                        prices for all such drugs and biologicals as 
                        may be necessary to audit the information so 
                        reported or required to be reported; and
                            ``(iii) provide the Secretary with access 
                        to such records in order to permit the 
                        Secretary to audit information so reported or 
                        required to be reported.
                    ``(B) Penalties.--The provisions of section 
                1927(b)(3)(C) shall apply with respect to the reporting 
                of information under subparagraph (A) in the same 
                manner as it applies to the reporting of information 
                under section 1927(b)(3)(A), except that the reference 
                in clause (i) of such section to $10,000 is deemed a 
                reference to $100,000 and any reference to a suspension 
                of an agreement is deemed a reference to a suspension 
                of payment for the drug or biological involved under 
                this part. The Secretary shall promptly refer to the 
                Inspector General of the Department of Health and Human 
                Services and, if appropriate, to appropriate officials 
                in the Department of Justice cases in which the 
                Secretary becomes aware of a false price representation 
                made in the information submitted under this paragraph.
                    ``(C) Form of reporting.--Information required to 
                be reported under subparagraph (A)(i) shall be reported 
                in a form and manner specified by the Secretary. The 
                information required to be reported shall include the 
                identification of the generic name of the drug or 
                biological and its brand name (if any), the national 
                drug code (NDC) and the HCPCS code assigned to the drug 
                or biological, the dosage form, strength, volume, and 
                package size involved. The information for a quarter 
                shall be submitted not later than 30 days after the end 
                of the quarter. The information shall be accompanied by 
                a written and signed certification by an officer of the 
                manufacturer attesting to the accuracy of the 
                information reported. Such information shall include 
                updated information on the net price realized (taking 
into account rebates and other amounts affecting net price), regardless 
of the period for which such a rebate or other adjustment in net price 
might have been earned.
                    ``(D) Auditing.--The Secretary shall audit on a 
                periodic basis information reported or required to be 
                reported under this paragraph. The Secretary may 
                conduct such independent price gathering activities, 
                such as surveys and review of published catalog 
                information or other transactional information, as may 
                be appropriate to verify the accuracy of the 
                information reported.
            ``(4) Dispensing fee.--If payment for a drug or biological 
        is made to a licensed pharmacy approved to dispense drugs or 
        biologicals under this part, the Secretary shall pay a 
        dispensing fee (less the applicable deductible and coinsurance 
        amounts) to the pharmacy. Such a dispensing fee shall be 
        subject to adjustment from year to year based upon changes in 
        the consumer price index over time and may be adjusted as the 
        Secretary determines to be appropriate to reflect differences 
        in the costs of dispensing different drugs and biologicals.
            ``(5) Payment required on an assignment-related basis.--
                    ``(A) In general.--Payment for a charge for any 
                drug or biological for which payment may be made under 
                this part may be made only on an assignment-related 
                basis.
                    ``(B) Application of enforcement provisions.--The 
                provisions of subsection (b)(18)(B) shall apply to 
                charges for such drugs or biologicals in the same 
                manner as they apply to services furnished by a 
                practitioner described in subsection (b)(18)(C).''.
            (2) Effective date.--Subject to subsection (c)(2), the 
        amendment made by paragraph (1) shall apply to drugs and 
        biologicals furnished on or after January 1, 2003.
    (b) Revision in Practice Expense Payments.--
            (1) Adjustment in oncologist medical supply expenses.--In 
        computing the practice expense component of the physician fee 
        schedule under section 1848 of the Social Security Act (42 
        U.S.C. 1395w-4) with respect to payment for services of 
        oncologists, the Secretary of Health and Human Services shall 
        make adjustments to oncologists' reported medical supply 
        expenses in order to ensure that such expenses better reflect 
        the actual supply costs of providing such services.
            (2) Allocation of indirect expenses.--In establishing such 
        fee schedule, the Secretary shall change the allocation of 
        indirect expenses in a manner so that all services, including 
        services without direct physician involvement, are allocated 
        the appropriate share of indirect expenses.
            (3) Services without direct physician involvement.--In 
        establishing such fee schedule, the Secretary shall calculate 
        payments, for those services without direct physician 
        involvement under the basic method, using information on the 
        resources required for each services and, if deemed necessary, 
        shall validate the underlying resource-based estimates of 
        direct practice expenses required to provide each service.
            (4) Budget neutral adjustment.--The changes in payment made 
        by this subsection shall not be treated as a change in law or 
        regulation described in section 1848(f)(2)(D) of the Social 
        Security Act (42 U.S.C. 1395w-4(f)(2)(D)).
            (5) Effective date.--The provisions of this subsection 
        apply to payments for services furnished on or after January 1, 
        2003.
    (c) Study of Payments for Blood Clotting Factors and Other 
Biologicals.--
            (1) In general.--The Secretary of Health and Human Services 
        shall provide for a study of the appropriateness of the 
        medicare payment methodology for blood clotting factors and 
        other biologicals under part B of title XVIII of the Social 
        Security Act. Not later than 9 months after the date of the 
        enactment of this Act, the Secretary shall submit to Congress a 
        report on such study and shall include in such report 
        recommendations regarding whether to apply the payment 
        methodology provided under the amendment made by subsection 
        (a)(1) and alternative recommendations for appropriate 
        dispensing fees.
            (2) Delay in effective date.--The amendment made by 
        subsection (a)(1) shall not apply to blood clotting factors 
        furnished before the first day of the first calendar year that 
        begins at least 6 months after the date the report under 
        paragraph (1) has been submitted to the Congress.
answer:

Medicare Market Acquisition Drug Price Act of 2002 - Amends title XVIII (Medicare) of the Social Security Act (SSA) to revise payment for drugs and biologicals under Medicare.Directs the Secretary of Health and Human Services, in computing the practice expense component of the Medicare physician fee schedule with respect to payment for services of oncologists, to make adjustments to an oncologist's reported medical supply expenses in order to ensure that they better reflect the actual supply costs of providing such services.